Combination recombinant interleukin-2, recombinant interferon-alpha, and 5-fluorouracil for treatment of metastatic renal cell carcinoma.
Ueno
N T
NT
Department of Genitourinary Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Zukiwski
A A
AA
D002292:Carcinoma, Renal Cell / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use
D007370:Interferon Type I; D007376:Interleukin-2; D011994:Recombinant Proteins; D005472:Fluorouracil